Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total β cell destruction in glucagon receptor-null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose-responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insulin resistance and concurrent relative insulin deficiency and glucagon dysregulation underlie T2D pathophysiology.33–35”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alterations in these mechanisms lead to an increased fasting glucose production and impaired hepatic glucose uptake, contributing to the pathogenesis of type 2 diabetes (T2D) [1].”
From Modeling the effect of glucagon on endogenous glucose production in healthy individuals under meal-like conditions (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532
The unique cytoarchitecture of human pancreatic islets has implications for islet cell function
Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P.-O., & Caicedo, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510790103 · Cited by 1,312
Brüning, J. C., Michael, M. D., Winnay, J. N., Hayashi, T., Hörsch, D., Accili, D., Goodyear, L. J., & Kahn, C. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80155-0 · Cited by 1,182
CREB and the CRTC co-activators: sensors for hormonal and metabolic signals
Altarejos, J. Y., & Montminy, M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3072 · Cited by 1,040
(1922) · PubMed · Cited by 753
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Self-citationα-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Research works printed but not linked: 10
- Banting, 1922, Can Med Assoc J., 12, 141
- Cherrington, 1978, Biochem Soc Symp., 43, 31
- Exton, 1970, Recent Prog Horm Res., 26, 411
- Cherrington, 1979, Am J Physiol., 236, E263
- Davis, 1985, Am J Physiol., 248, E463
- Wada, 1995, Am J Physiol., 268, E194
- Holste, 1997, Am J Physiol., 273, E488
- Baum, 1962, Diabetes., 11, 371
- Meda, 1981, C R Seances Acad Sci III., 293, 607
- Cherrinton AD. Control of glucose production in vivo by insulin and glucagon. In:Handbook of Physiology . Vol. 2. 2011:759–785. · DOI · Paper page
Cited by
Items 101–200 of 682
20 years of leptin: From the discovery of the leptin gene to leptin in our therapeutic armamentarium
Friedman, J. M., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.10.023 · Cited by 101
Karwi, Q. G., Zhang, L., Wagg, C. S., Wang, W., Ghandi, M., Thai, D. L., Yan, H., Ussher, J. R., Oudit, G. Y., & Lopaschuk, G. D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0806-4 · Cited by 94
Manell, H., Staaf, J., Manukyan, L., Kristinsson, H., Cen, J., Stenlid, R., Ciba, I., Forslund, A. H., & Bergsten, P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3885 · Cited by 99
Tolbutamide Controls Glucagon Release From Mouse Islets Differently Than Glucose
Cheng-Xue, R., Gómez-Ruiz, A., Antoine, N., Noël, L. A., Chae, H.-Y., Ravier, M. A., Chimienti, F., Schuit, F. C., & Gilon, P. (2013) · Diabetes · doi:10.2337/db12-0347 · Cited by 89
“The importance of this duality of secretion of both hormones was suggested by the idea that both lack of insulin and chronic hyperglucagonemia are needed to trigger overt diabetes (1).”
BackgroundOf rodents and men: Species-specific glucose regulation and type 2 diabetes research
Chandrasekera, P. C. (2014) · ALTEX · doi:10.14573/1309231 · Cited by 89
“With 70-80% of β-cells juxtaposed to α-cells in humans, intra-islet insulin secretion prevents hyperglucagonemia, and unregulated α-cells hypersecrete glucagon, thereby generating a diabetic phenotype (Unger and Cherrington, 2012), whereas these interactions are different in rodents with different pancreatic cytoarchi…”
Genetic risk converges on regulatory networks mediating early type 2 diabetes
Walker, J. T., Saunders, D. C., Rai, V., Chen, H., Orchard, P., Dai, C., Pettway, Y. D., Hopkirk, A. L., Reihsmann, C., Tao, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06693-2 · Cited by 93
Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes
Scheen, A. J., Paquot, N., & Lefèbvre, P. J. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1395020 · Cited by 87
“Recent experimental data in animal models of diabetes have suggested that glucagon excess rather than insulin deficiency is the sine qua non of diabetes [10].”
BackgroundImproved methodologies for the study of adipose biology: insights gained and opportunities ahead
Wang, Q. A., Scherer, P. E., & Gupta, R. K. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046441 · Cited by 85
The Human Islet: Mini-Organ With Mega-Impact
Walker, J. T., Saunders, D. C., Briššová, M., & Powers, A. C. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab010 · Cited by 97
What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?
Kuhre, R. E., Deacon, C. F., Holst, J. J., & Petersen, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.694284 · Cited by 78
Bedinger, D., & Adams, S. H. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.08.013 · Cited by 95
Glucose controls glucagon secretion by directly modulating cAMP in alpha cells
Yu, Q., Shuai, H., Ahooghalandari, P., Gylfe, E., & Tengholm, A. (2019) · Diabetologia · doi:10.1007/s00125-019-4857-6 · Cited by 84
Glucagon's Metabolic Action in Health and Disease
Zeigerer, A., Sekar, R., Kleinert, M., Nason, S., Habegger, K. M., & Müller, T. D. (2021) · Comprehensive Physiology · doi:10.1002/cphy.c200013 · Cited by 59
“Indeed, postprandial glucagon levels are higher in all forms of diabetes, including type-1 and type-2 diabetes (383).”
Meek, T. H., Wisse, B. E., Thaler, J. P., Guyenet, S. J., Matsen, M. E., Fischer, J. D., Taborsky, G. J., Schwartz, M. W., & Morton, G. J. (2013) · Diabetes · doi:10.2337/db12-0837 · Cited by 80
“Glucagon increases plasma glucose levels by stimulating HGP, and several lines of evidence suggest that hyperglucagonemia contributes to elevated blood glucose levels in uncontrolled insulin-deficient diabetes (19).”
BackgroundRamadan and Diabetes: A Narrative Review and Practice Update
Ahmed, S. H., Chowdhury, T. A., Hussain, S., Syed, A., Karamat, A., Helmy, A., Waqar, S., Ali, S., Dabhad, A., Seal, S. T., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00886-y · Cited by 87
“Hyperglucagonaemia in T2 diabetes is a well-recognized contributor to hyperglycaemia by stimulating increased hepatic production, but the risk of ketoacidosis is low due to the relative presence of insulin [15, 16].”
BackgroundDiscovering signaling mechanisms governing metabolism and metabolic diseases with Drosophila
Kim, S. K., Tsao, D. D., Suh, G. S. B., & Miguel‐Aliaga, I. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.05.018 · Cited by 83
Glucagon and heart in type 2 diabetes: new perspectives
Ceriello, A., Genovese, S., Mannucci, E., & Gronda, E. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0440-3 · Cited by 77
“In this view, glucagon has been recently suggested as the key feature of type 2 diabetes [30].”
BackgroundIslet prohormone processing in health and disease
Chen, Y., Taylor, A. J., & Verchere, C. B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13401 · Cited by 86
Regulation of islet glucagon secretion: Beyond calcium
Hughes, J. W., Ustione, A., Lavagnino, Z., & Piston, D. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13381 · Cited by 73
“The therapeutic benefits of insulin in diabetes have led most research to focus on the insulin-secreting β-cells(7) even though we now know that aberrant glucagon secretion from α-cells exacerbates hyperglycaemia in diabetes.(8,9) In particular, glucagon suppression by”
BackgroundGlucagon receptor antagonism induces increased cholesterol absorption
Guan, H.-P., Yang, X., Lu, K., Wang, S.-P., Castro-Perez, J. M., Previs, S., Wright, M., Shah, V., Herath, K., Xie, D., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m060897 · Cited by 76
Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin
Vanderheiden, A., Harrison, L. B., Warshauer, J. T., Adams-Huet, B., Li, X., Yuan, Q., Hulsey, K., Dimitrov, I., Yokoo, T., Jaster, A. W., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3906 · Cited by 76
Dual‐hormone artificial pancreas: benefits and limitations compared with single‐hormone systems
Peters, T. M., & Haidar, A. (2018) · Diabetic Medicine · doi:10.1111/dme.13581 · Cited by 71
Role of Glucagon in Catabolism and Muscle Wasting of Critical Illness and Modulation by Nutrition
Thiessen, S. E., Derde, S., Derese, I., Dufour, T., Vega, C. A., Langouche, L., Goossens, C., Peersman, N., Vermeersch, P., Vander Perre, S., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201702-0354oc · Cited by 75
Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist
Damond, N., Thorel, F., Moyers, J. S., Charron, M. J., Vuguin, P. M., Powers, A. C., & Herrera, P. L. (2016) · eLife · doi:10.7554/elife.13828 · Cited by 74
“These findings lead to hypothesize that glucagon is 37 responsible for the features of diabetes (12).”
InfluentialPan, A., Sun, X., Huang, F., Liu, J., Cai, Y., Xin, W., Alolga, R. N., Li, P., Liu, B., Liu, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28044-x · Cited by 77
Alolga, R. N., Nuer-Allornuvor, G. F., Kuugbee, E. D., Yin, X., & Ma, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104630 · Cited by 76
Towards a Functional Cure for Diabetes Using Stem Cell-Derived Beta Cells: Are We There Yet?
Bourgeois, S., Sawatani, T., Mulders, A. V., Leu, N. D., Heremans, Y., Heimberg, H., Cnop, M., & Staels, W. (2021) · Cells · doi:10.3390/cells10010191 · Cited by 77
Diabetes-related alterations in the enteric nervous system and its microenvironment
Bagyánszki, M. (2012) · World Journal of Diabetes · doi:10.4239/wjd.v3.i5.80 · Cited by 71
Glucose control of glucagon secretion—‘There’s a brand-new gimmick every year’
Gylfe, E. (2016) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2016.1154905 · Cited by 75
“Insulin released from the b-cells was first proposed (43) and is still considered as a putative mediator of glucose-inhibited glucagon secretion (18,44).”
BackgroundGlucagon: acute actions on hepatic metabolism
Miller, R., & Birnbaum, M. J. (2016) · Diabetologia · doi:10.1007/s00125-016-3955-y · Cited by 75
Cantley, J. (2014) · Mammalian Genome · doi:10.1007/s00335-014-9538-7 · Cited by 76
“2005): this mechanism may promote glucose homeostasis by preventing hyperglucagonaemia, a deleterious feature of T2D (Unger and Cherrington 2012).”
BackgroundLi, J. H., Jain, S., McMillin, S. M., Cui, Y., Gautam, D., Sakamoto, W., Lü, H., Jou, W., McGuinness, O. P., Gavrilova, O., et al. (2013) · Endocrinology · doi:10.1210/en.2012-2127 · Cited by 78
“Given the critical role of increased HGP in the pathophysiology of T2D, our findings may lead to new avenues to modulate liver glucose fluxes for therapeutic purposes.”
BackgroundInfluentialLiu, S., Kilic, G., Meyers, M. S., Navarro, G., Wang, Y., Oberholzer, J., & Mauvais-Jarvis, F. (2013) · Diabetologia · doi:10.1007/s00125-012-2764-1 · Cited by 73
“This observation is also consistent with the ‘glucagonocentric’ vision of diabetes pathophysiology in which glucagon excess, rather than insulin deficiency, is the sine qua non of hyperglycaemia in all forms of diabetes, at least in rodents [40].”
ResultJohswich, A., Longuet, C., Pawling, J., Rahman, A. M. A., Ryczko, M. C., Drucker, D. J., & Dennis, J. W. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.563734 · Cited by 77
“Herein we have focused on Gcgr, because the action of glucagon is critically important for the development of hyperglycemia and insulin resistance (1, 2).”
Beta-Cell Fragility As a Common Underlying Risk Factor in Type 1 and Type 2 Diabetes
Liston, A., Todd, J. A., & Lagou, V. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.12.005 · Cited by 75
Miyachi, A., Kobayashi, M., Mieno, E., Goto, M., Furusawa, K., Inagaki, T., & Kitamura, T. (2017) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-017-0534-0 · Cited by 71
CNS control of the endocrine pancreas
Faber, C. L., Deem, J. D., Campos, C., Taborsky, G. J., & Morton, G. J. (2020) · Diabetologia · doi:10.1007/s00125-020-05204-6 · Cited by 74
“To further support this notion, it has been reported that: (1) the effect of hyperglycaemia to suppress glucagon secretion is blunted in diabetes; (2) glucagon receptor-null mice are protected from streptozotocin-induced diabetes; and (3) suppression of glucagon secretion has been suggested as a strategy for treatment…”
BackgroundResultBrun, P., Grijalva, A., Rausch, R. N., Watson, E., Yuen, J. J., Das, B. C., Shudo, K., Kagechika, H., Leibel, R. L., & Blaner, W. S. (2014) · The FASEB Journal · doi:10.1096/fj.14-256743 · Cited by 79
“Thus, our findings that the RARdn mice are euglycemic, despite a diminished insulin response to a glucose challenge, are in agreement with the Unger/Cherrington (38, 39) formulation regarding the role of glucagon as the proximal regulator of plasma glucose levels, even during insulin deficiency.”
BackgroundResultInfluentialThe Somatostatin Receptor in Human Pancreatic β-Cells
Braun, M. (2014) · Vitamins and hormones · doi:10.1016/b978-0-12-800174-5.00007-7 · Cited by 80
“SST analogues have not been further pursued as diabetes drugs in recent years (Unger & Cherrington, 2012).”
BackgroundMitoNEET-Parkin Effects in Pancreatic α- and β-Cells, Cellular Survival, and Intrainsular Cross Talk
Kusminski, C. M., Chen, S., Ye, R., Sun, K., Wang, Q. A., Spurgin, S. B., Sanders, P. E., Brozinick, J. T., Geldenhuys, W. J., Li, W.-H., et al. (2016) · Diabetes · doi:10.2337/db15-1323 · Cited by 69
“Therefore, targeting a-cell–derived glucagon excess to eliminate diabetic glycemic volatility is appealing for the treatment of T2DM such that novel avenues aimed to suppress glucagon hypersecretion or signaling should prove beneficial (20).”
BackgroundSelf-citationNutrient-Sensing Mechanisms in the Gut as Therapeutic Targets for Diabetes
Breen, D. M., Rasmussen, B. A., Côté, C. D., Jackson, V. M., & Lam, T. K. T. (2013) · Diabetes · doi:10.2337/db13-0523 · Cited by 65
“The effect of leptin to lower glucose concentrations in insulin-deficient conditions has been attributed to a lowering of plasma glucagon levels (3), implicating glucagon action (instead of insulin resistance) as a potential major driver of hyperglycemia (8).”
BackgroundAli, S., Ussher, J. R., Baggio, L. L., Kabir, M. G., Charron, M. J., Ilkayeva, O., Newgard, C. B., & Drucker, D. J. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2014.11.005 · Cited by 69
“Collectively, these findings have raised enthusiasm for glucagon antagonism as a potential therapeutic strategy for T2D.”
BackgroundInfluentialYabe, D., Kuroe, A., Watanabe, K., Iwasaki, M., Hamasaki, A., Hamamoto, Y., Harada, N., Yamane, S., Lee, S., Murotani, K., et al. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.12.010 · Cited by 69
Neurotransmitter control of islet hormone pulsatility
Gylfe, E., & Tengholm, A. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12345 · Cited by 64
“Although insufficient secretion of insulin is the generally accepted cause of diabetes, it was recently proposed that ‘glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes’ [3].”
Backgroundde Matos, A. M., de Macedo, M. P., & Rauter, A. P. (2018) · Medicinal Research Reviews · doi:10.1002/med.21440 · Cited by 66
Effect of a glucagon receptor antibody (REMD‐477) in type 1 diabetes: A randomized controlled trial
Pettus, J., Reeds, D., Cavaiola, T. S., Boeder, S., Levin, M., Tobin, G., Cava, E., Thai, D., Shi, J., Yan, H., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13202 · Cited by 67
Self-citationGLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes
Halden, T. A. S., Egeland, E. J., Åsberg, A., Hartmann, A., Midtvedt, K., Khiabani, H. Z., Holst, J. J., Knop, F. K., Hornum, M., Feldt-Rasmussen, B., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2383 · Cited by 67
“In nontransplanted patients, type 2 diabetes is characterized by insulin resistance and b-cell failure in addition to inappropriate a-cell function that result in fasting and postprandial hyperglucagonemia (8), both of which contribute to the hyperglycemic state of the patients (9).”
BackgroundKarimian, N., Qin, T., Liang, T., Osundiji, M., Huang, Y., Teich, T., Riddell, M. C., Cattral, M. S., Coy, D. H., Vranic, M., et al. (2013) · Diabetes · doi:10.2337/db13-0164 · Cited by 66
Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status
Hu, C., Chen, Y., Yin, X., Xu, R., Yin, C., Wang, C., & Zhao, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02098-3 · Cited by 89
FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs
Kim, K. H., & Lee, M. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0160 · Cited by 71
“Hyperglucagonemia is observed in the early phase of insulin resistance/T2D and contributes to hyperglycemia by increasing the rate of hepatic glucose output and enhancing glycogen breakdown (Unger & Cherrington 2012).”
BackgroundGlycemia Regulation: From Feedback Loops to Organizational Closure
Bich, L., Mossio, M., & Soto, A. M. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00069 · Cited by 75
Walker, J. T., Haliyur, R., Nelson, H. A., Ishahak, M., Poffenberger, G., Aramandla, R., Reihsmann, C., Luchsinger, J. R., Saunders, D. C., Wang, P., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.137017 · Cited by 58
The Difference δ-Cells Make in Glucose Control
Huising, M. O., van der Meulen, T., Huang, J. L., Pourhosseinzadeh, M. S., & Noguchi, G. M. (2018) · Physiology · doi:10.1152/physiol.00029.2018 · Cited by 59
Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives
Ahrén, B. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.03.001 · Cited by 64
Recent progress on the role of ChREBP in glucose and lipid metabolism [Review]
Iizuka, K. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej13-0121 · Cited by 76
Peptide regulators of peripheral taste function
Dotson, C. D., Geraedts, M. C. P., & Munger, S. D. (2013) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2013.01.004 · Cited by 62
Alpha-cell paracrine signaling in the regulation of beta-cell insulin secretion
Holter, M. M., Saikia, M., & Cummings, B. P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.934775 · Cited by 63
SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control
Montgomery, M. K., Bayliss, J., Devereux, C., Bezawork-Geleta, A., Roberts, D., Huang, C., Schittenhelm, R. B., Ryan, A., Townley, S. L., Selth, L. A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz8048 · Cited by 63
Xiao, N., Lou, M., Lu, Y., Yang, L., Liu, Q., Liu, B., Qi, L., & Li, P. (2017) · Diabetologia · doi:10.1007/s00125-017-4238-y · Cited by 62
“It is therefore proposed that suppression of hepatic glucagon response may provide therapeutic advantages in diabetes management [6].”
BackgroundReduced somatostatin signalling leads to hypersecretion of glucagon in mice fed a high-fat diet
Kellard, J. A., Rorsman, N. J. G., Hill, T. G., Armour, S. L., van de Bunt, M., Rorsman, P., Knudsen, J. G., & Briant, L. J. B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101021 · Cited by 67
“However, it 39 is also recognized that abnormal glucagon secretion contributes to the development of glucose 40 intolerance and that T2D is best characterized as a bihormonal disorder [1, 2].”
BackgroundAlpha cell dysfunction in type 1 diabetes
Yosten, G. L. C. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.001 · Cited by 62
“In patients with T2D, hyperglucagonemia is thought to be due to resistance of the alpha cell to the suppressive effects of insulin and hyperglycemia, as well as to the dysregulation of incretins (e.g. glucosedependent insulinotropic polypeptide, GIP, and glucagon-like peptide 1, GLP-1), which can alter glucagon releas…”
BackgroundInfluentialInfante, M., Baidal, D. A., Rickels, M. R., Fabbri, A., Skyler, J. S., Alejandro, R., & Ricordi, C. (2021) · Artificial Organs · doi:10.1111/aor.14023 · Cited by 66
Energy intake, metabolic homeostasis, and human health
Pang, G., Xie, J., Chen, Q., & Zhi-he, H. (2014) · Food Science and Human Wellness · doi:10.1016/j.fshw.2015.01.001 · Cited by 76
Conrad, E., Dai, C., Spaeth, J., Guo, M., Cyphert, H. A., Scoville, D., Carroll, J., Yu, W.-M., Goodrich, L. V., Harlan, D. M., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00285.2015 · Cited by 61
Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol
Spolitu, S., Okamoto, H., Dai, W., Zadroga, J. A., Wittchen, E. S., Gromada, J., & Ozcan, L. (2019) · Circulation Research · doi:10.1161/circresaha.118.313648 · Cited by 64
Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes
Jia, Y., Liu, Y., Feng, L., Sun, S., & Sun, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.928016 · Cited by 68
Glucagon actions on the kidney revisited: possible role in potassium homeostasis
Bankir, L., Bouby, N., Blondeau, B., & Crambert, G. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00560.2015 · Cited by 61
“A new interest in glucagon has arisen when it was rediscovered that the metabolic disorders observed in diabetes mellitus (DM) are not, or not only due to the lack of insulin or to insulin resistance of the target tissues, but to elevated glucagon levels (6, 66, 103, 106, 107, 164, 194).”
BackgroundJun, L. S., Millican, R. L., Hawkins, E. D., Konkol, D. L., Showalter, A. D., Christe, M. E., Michael, M. D., & Sloop, K. W. (2015) · Diabetes · doi:10.2337/db14-1052 · Cited by 60
“These results are similar to those showing acute blockade of the GLP-1R using exendin-4(9-39) worsens glucose tolerance in STZ-treated Gcgr-null mice (19).”
BackgroundMethodResultInfluentialFunctional identification of islet cell types by electrophysiological fingerprinting
Briant, L. J. B., Zhang, Q., Vergari, E., Kellard, J. A., Rodriguez, B., Ashcroft, F. M., & Rorsman, P. (2017) · Journal of The Royal Society Interface · doi:10.1098/rsif.2016.0999 · Cited by 59
Pettus, J., Boeder, S. C., Christiansen, M. P., Denham, D. S., Bailey, T. S., Akturk, H. K., Klaff, L. J., Rosenstock, J., Cheng, M. H. M., Bode, B. W., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02011-x · Cited by 54
High-fidelity Glucagon-CreER mouse line generated by CRISPR-Cas9 assisted gene targeting
Ackermann, A. M., Zhang, J., Heller, A., Briker, A., & Kaestner, K. H. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.01.003 · Cited by 59
“This is exhibit inappropriately low glucagon levels during hypoglycemia [6] but inappropriately elevated glucagon levels during hyperglycemia [3], leading to broad and unpredictable glucose fluctuations.”
BackgroundHorie, I., Abiru, N., Eto, M., Sako, A., Akeshima, J., Nakao, T., Nakashima, Y., Niri, T., Ito, A., Nozaki, A., et al. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12829 · Cited by 59
Substrate-selective inhibitors that reprogram the activity of insulin-degrading enzyme
Maianti, J. P., Tan, G. A., Vetere, A., Welsh, A. J., Wagner, B. K., Seeliger, M. A., & Liu, D. R. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0271-0 · Cited by 61
Rajas, F., Labrune, P., & Mithieux, G. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.03.002 · Cited by 60
“[30] Unger RH, Cherrington AD.”
Glucagon orchestrates stress‐induced hyperglycaemia
Harp, J. B., Yancopoulos, G. D., & Gromada, J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12668 · Cited by 61
Regulation of amino acid metabolism and α‐cell proliferation by glucagon
Hayashi, Y., & Seino, Y. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12797 · Cited by 59
Singer, R. A., Arnes, L., Cui, Y., Wang, J., Gao, Y., Guney, M. A., Burnum-Johnson, K., Rabadán, R., Ansong, C. K., Orr, G., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.013 · Cited by 59
“While the majority of diabetes treatment options have focused on enhancing β cell function to meet insulin demands, more recent work has shown that α cell dysfunction and hyperglucagonemia also contribute to disease pathophysiology (Unger and Cherrington, 2012; Brissova et al., 2018).”
BackgroundGLP-1 receptor signaling increases PCSK1 and β cell features in human α cells
Saikia, M., Holter, M. M., Donahue, L. R., Lee, I. S., Zheng, Q. C., Wise, J. L., Todero, J. E., Phuong, D. J., Garibay, D., Coch, R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.141851 · Cited by 57
“JCI Insight 2021;6(3):e141851 https://doi.”
BackgroundInfluentialManell, H., Kristinsson, H., Kullberg, J., Ubhayasekera, S. J. K. A., Mörwald, K., Staaf, J., Cadamuro, J., Zsoldos, F., Göpel, S., Sargsyan, E., et al. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12890 · Cited by 60
Habener, J. F., & Stanojevic, V. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.10.009 · Cited by 62
Levetan, C. S., & Pierce, S. M. (2012) · Endocrine Practice · doi:10.4158/ep12138.ra · Cited by 60
Spaeth, J. M., Hunter, C. S., Bonatakis, L., Guo, M. A., French, C. A., Slack, I. F., Hara, M., Fisher, S. E., Ferrer, J. P., Morrisey, E. E., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3635-3 · Cited by 54
“Although lesser studied, increasing evidence supports the importance of alpha cell dysregulation in the aetiology of both type 1 and type 2 diabetes [2].”
Genetic dissection of sleep–metabolism interactions in the fruit fly
Yurgel, M. E., Masek, P., DiAngelo, J., & Keene, A. C. (2015) · Journal of Comparative Physiology A · doi:10.1007/s00359-014-0936-9 · Cited by 51
“In mammals, the peptide hormones insulin and glucagon are critical for regulation of blood-glucose levels and energy availability (Saltiel and Kahn 2001; Unger and Cherrington 2012).”
Mini‐review: Glucagon responses in type 1 diabetes – a matter of complexity
Bengtsen, M. B., & Møller, N. (2021) · Physiological Reports · doi:10.14814/phy2.15009 · Cited by 64
“…following a meal could relate to low paracrine pancreatic insulin levels and supports the hypothesis that hyperglucagonemia plays a significant role in the pathogenesis of hyperglycemia leading to tissue glucotoxicity and thereby insulin resistance in type 1 diabetes (Unger & Cherrington, 2012).”
BackgroundKim, A., Knudsen, J. G., Madara, J. C., Benrick, A., Hill, T., Kadir, L. A., Kellard, J. A., Mellander, L., Miranda, C., Lin, H., et al. (2021) · eLife · doi:10.7554/elife.72919 · Cited by 54
Extreme Beta-Cell Deficiency in Pancreata of Dogs with Canine Diabetes
Shields, E. J., Lam, C. J., Cox, A. R., Rankin, M. M., Winkle, T. J. V., Hess, R. S., & Kushner, J. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129809 · Cited by 57
El Youssef, J., Castle, J. R., Bakhtiani, P. A., Haidar, A., Branigan, D. L., Breen, M., & Ward, W. K. (2014) · Diabetes Care · doi:10.2337/dc14-0803 · Cited by 52
“Althoughb-cell dysfunction is known to be the hallmark of type 1 and type 2 diabetes (2,3), a-cell dysfunction in both of these conditions may also contribute to the diabetic condition (4).”
BackgroundBerberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3
Zhang, B., Pan, Y., Xu, L., Tang, D., Dorfman, R. G., Zhou, Q., Yin, Y., Yang, L., Zhou, L., Zhao, S., et al. (2018) · Endocrine · doi:10.1007/s12020-018-1689-y · Cited by 55
Ojha, A., Ojha, U., Mohammed, R., Chandrashekar, A., & Ojha, H. (2019) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s202614 · Cited by 70
“Their coordination is essential for glucose homeostasis.(6)”
Nuttall, F. Q., Almokayyad, R. M., & Gannon, M. C. (2014) · Metabolism · doi:10.1016/j.metabol.2014.10.004 · Cited by 51
“This could be attributed to a decrease in insulin concentration [34] and an increase in non-esterified fatty acids (NEFAs) [35].”
BackgroundBarbagallo, D., Piro, S., Condorelli, A. G., Mascali, L. G., Urbano, F., Parrinello, N. L., Monello, A., Statello, L., Ragusa, M., Rabuazzo, A. M., et al. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-62 · Cited by 62
“It is associated to α cells dysfunctions and high glucagon secretion, which contribute to chronic hyperglycemia and ensuing clinical outcomes in DM [6,7].”
ZIGIR, a Granule-Specific Zn2+ Indicator, Reveals Human Islet α Cell Heterogeneity
Zadeh, E. H. G., Huang, Z., Xia, J., Li, D., Davidson, H. W., & Li, W.-H. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107904 · Cited by 52
“Over the past decade, there has been increasing appreciation for the role of α cells and glucagon secretion in diabetes research (Unger and Cherrington, 2012).”
BackgroundEvolving function and potential of pancreatic alpha cells
Stanojevic, V., & Habener, J. F. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.10.002 · Cited by 59
Yagihashi, S., Inaba, W., & Mizukami, H. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12424 · Cited by 51
Mu, J., Qureshi, S. A., Brady, E. J., Muise, E. S., Candelore, M. R., Jiang, G., Li, Z., Wu, M. S., Yang, X., Dallas-Yang, Q., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049572 · Cited by 50
“Dysregulation of glucagon has received less attention in this regard, but is also thought to play an important role in diabetes [3,6].”
BackgroundMafB Is Critical for Glucagon Production and Secretion in Mouse Pancreatic α Cells In Vivo
Katoh, M., Jung, Y., Ugboma, C. M., Shimbo, M., Kuno, A., Basha, W. A. A., Kudo, T., Oishi, H., & Takahashi, S. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00504-17 · Cited by 54
Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain
Scarlett, J. M., Muta, K., Brown, J. M., Rojas, J. M., Matsen, M. E., Acharya, N. K., Secher, A., Ingvorsen, C., Jorgensen, R., Høeg-Jensen, T., et al. (2019) · Diabetes · doi:10.2337/db18-0498 · Cited by 50
“Excess glucagon secretion also has been hypothesized to drive diabetic hyperglycemia (41), and plasma glucagon levels were signi fi cantly decreased in ZDF rats receiving icv FGF1 compared with icv Veh.”
Li, A., Liu, Q., Li, Q., Liu, B., Yang, Y., & Zhang, N. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.07.039 · Cited by 49
Islet sympathetic innervation and islet neuropathology in patients with type 1 diabetes
Campbell‐Thompson, M., Butterworth, E. A., Boatwright, J. L., Nair, M. A., Nasif, L. H., Nasif, K., Revell, A. Y., Riva, A., Mathews, C. E., Gerling, I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85659-8 · Cited by 49
Gar, C., Haschka, S. J., Kern-Matschilles, S., Rauch, B., Sacco, V., Prehn, C., Adamski, J., Seissler, J., Wewer Albrechtsen, N. J., Holst, J. J., et al. (2021) · Diabetologia · doi:10.1007/s00125-020-05334-x · Cited by 44
“Indeed, inhibition of glucagon signalling by treatment with a glucagon receptor antagonist has shown favourable effects on glucose metabolism in individuals with type 2 diabetes [1, 2].”
Background
Metadata
- Authors
- Unger, R. H., & Cherrington, A. D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Unger, Roger H.
- ORCID
- Cherrington, Alan D.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-01-03
- Volume
- 122
- Issue
- 1
- Pages
- 4-12
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3248306
- OpenAlex
- W2113278846
- Cited by
- 670
- References
- 100
- Citations by year
- 2026: 30 · 2025: 28 · 2024: 38 · 2023: 41 · 2022: 36 · 2021: 46 · 2020: 45 · 2019: 48 · 2018: 68 · 2017: 54 · 2016: 49 · 2015: 56 · 2014: 57 · 2013: 48 · 2012: 26
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Amylin Pharmaceuticals
- University of Texas Southwestern Medical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon, hyperglucagonemia, diabetes pathophysiology, insulin deficiency, hepatic glucose production, ketogenesis, leptin, somatostatin, glucagon receptor, pancreatic beta cells, alpha cells, anti-insulin serum
- MeSH terms
- Animals, Diabetes Mellitus, Type 1, Glucagon, Humans, Insulin, Liver, Pancreas, Glycogenolysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.